UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
BIOTECHNOLOGY

Invizius

Biomaterial coatings to reduce immune response in medical devices

Invizius logo

Invizius

BiotechnologyEdinburgh, United Kingdom

Biomaterial coatings to reduce immune response in medical devices

Visit Website

About Invizius

Pioneering second-generation complement therapeutics, Invizius is a Scottish biotech company dedicated to improving outcomes for patients with autoimmune and inflammatory disorders, with a primary clinical focus on individuals undergoing extracorporeal treatments, including haemodialysis, cardiopulmonary bypass, and extracorporeal membrane oxygenation (ECMO). These patient groups face significant complement-driven complications that existing therapies fail to adequately address, leaving a well-documented gap in clinical care.

Complement Biology and the PspCN Platform

The company's core scientific platform centres on PspCN, a naturally derived complement regulator that modulates the complement cascade, a key component of the innate immune system implicated in systemic inflammation and tissue injury during extracorporeal procedures. PspCN serves as the foundation of Invizius's therapeutic pipeline and distinguishes the company from first-generation complement inhibitors that act on different pathway nodes. The approach targets the specific clinical settings where uncontrolled complement activation causes measurable patient harm.

Invizius draws on a clinical and scientific advisory board with expertise spanning nephrology, cardiac surgery, and immunology, and is supported by an investor and collaborator network suited to its early-stage development model. The company's pipeline has progressed towards clinical trials, reflecting growing confidence in the PspCN mechanism and its applicability across extracorporeal indications.

Incorporated and registered in Scotland, Invizius Limited (SC586903) operates from Edinburgh, with its registered office at Orchard Brae House, 30 Queensferry Road, EH4 2HS. The company is registered for VAT in the United Kingdom.

Further information is available at invizius.com.

Areas of Expertise

Cardiac SurgeryDrug DiscoveryNephrologyRare Disease

Services & Capabilities

Cardiac SurgeryDrug DiscoveryNephrologyRare Disease
Similar Companies

More in Biotechnology

A

Adcentrx Therapeutics

Founded in 2021 and headquartered in San Diego, California, Adcentrx Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for cancer and other life-threatening diseases. The company's work centres on its proprietary i-Conjugation platform, which addresses the principal engineering challenges of ADC design, including stable conjugation chemistry, cleavable linker technology, and controlled drug-antibody ratio (DAR 8), to maximise payload delivery to solid tumour cells while limiting systemic toxicity. Clinical Pipeline Adcentrx has advanced two candidates into Phase 1a/b clinical trials. ADRX-0706 is a Nectin-4 ADC currently in Phase 1b evaluation across a range of advanced solid tumours; the US FDA has granted it Fast Track Designation for locally advanced or metastatic squamous cell cervical cancer. ADRX-0405 is a STEAP1-targeting ADC in Phase 1a evaluation for metastatic castration-resistant prostate cancer, gastric cancer, and non-small cell lung cancer; it carries FDA Orphan Drug Designation for gastric cancer and is regarded as a potential first-in-class candidate for its target. Both programmes build on the i-Conjugation platform's aim to deliver best-in-class or first-in-class ADCs with differentiated clinical profiles. Funding & Partnerships Adcentrx has raised approximately $101 million across three financing rounds, including a Series A+ of $51 million led by Eight Roads Ventures and extended with participation from Quan Capital and Partners Investment. The company has entered a multi-target antibody discovery collaboration with AvantGen to source novel antibody candidates for its ADC pipeline. Further information is available at adcentrx.com.

View profile
A

ASLAN Pharmaceuticals

ASLAN Pharmaceuticals is a dual-listed (NASDAQ: ASLN; Taiwan Stock Exchange) clinical-stage biopharmaceutical company headquartered in Singapore, with operations in Taiwan and the United States. Founded in 2010, the company concentrates its pipeline on inflammatory diseases and oncology, with a particular strategic emphasis on conditions where patients lack effective treatment options. The company's lead asset is farudodstat (ASLAN004), a monoclonal antibody that blocks both the IL-13 receptor alpha-1 and IL-4 receptor alpha subunits. This dual mechanism is designed to address the full spectrum of type 2 inflammation and is being evaluated in moderate-to-severe atopic dermatitis and ulcerative colitis. ASLAN Pharmaceuticals has conducted Phase 2 studies across these indications, with clinical data guiding its ongoing development strategy. Pipeline Focus and Business Model ASLAN Pharmaceuticals operates a capital-light model, progressing internally discovered compounds through clinical proof-of-concept before seeking regional or global partnership arrangements. The company has previously evaluated oncology assets including varlitinib, a pan-ErbB inhibitor studied in biliary tract cancer and gastric cancer, and retains scientific capabilities across both immunology and oncology drug discovery. With its Asia-Pacific base, ASLAN is positioned to run efficient clinical programmes in markets with high patient enrolment potential, supporting faster data generation across its therapeutic areas. Further information is available at aslanpharma.com.

View profile
V

Vaccitech

Antigen-specific immunotherapy is the clinical focus of Barinthus Biotherapeutics plc (formerly Vaccitech), a clinical-stage biopharmaceutical company dedicated to guiding T cells and antibodies to overcome autoimmunity and inflammatory disease. The company operates at the research and development frontier of immunology and inflammatory (I&I) indications, building on scientific foundations laid by academic institutions of international standing. Barinthus Bio emerged from the 2021 merger of Vaccitech, Plc, an Oxford University spinout, and Avidea Technologies, Inc., a spinout of the National Institutes of Health (NIH) and Johns Hopkins University. The combination united two complementary immunotherapeutics platforms and created a company with a broader base of T cell-directed therapeutic expertise than either predecessor held independently. The company's pipeline centres on autoimmunity, with its proprietary SNAP-TI technology supporting the development of tolerance immunotherapies designed to address the underlying drivers of inflammatory disease rather than managing symptoms alone. Barinthus Bio describes its approach as guiding the immune system to cure disease, a distinction it draws between its antigen-specific methodology and broader immunosuppressive strategies common in the I&I space. Headquartered in the United Kingdom, the company is listed and engages institutional investors through structured governance and regular news and filings activity. Its scientific founders come from leading research institutions, anchoring its discovery capabilities in a heritage of cutting-edge immunological innovation. Further information is available at vaccitech.co.uk.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy